Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Curr Breast Cancer Rep. 2014 Feb 13;6(2):71–78. doi: 10.1007/s12609-014-0140-5

Table 1.

Clinical trials of AR-directed therapy in breast cancer

Therapy Phase Breast cancer Subtype Site/Sponsor Clinical Trials.gov Enrolment
Letrozole 2.5mg PO daily + DHEA 500 mg/1000mg PO daily 1 ER-Advanced disease in postmenopausal patients OHSU Knight Cancer Institute NCT00516542 Jul 2007–Dec 2010; Terminated due to poor accrual
Bicalutamide 150mg PO daily 2 AR+ TNBC, Advanced disease Memorial Sloan-Kettering Cancer Center NCT00468715 May 2007–Oct 2013; Completed
Enzalutamide 80mg and 160mg PO daily 1 Advanced disease Medivation NCT01597193 May 2012–current; ongoing
Enzalutamide 160mg PO daily 2 AR+ TNBC, Advanced disease Medivation NCT01889238 Jun 2013–current; ongoing
Abiraterone Acetate 1/2 Advanced disease in postmenopausal patients Cancer Research UK NCT00755885 Oct 2008–current, ongoing
Enobosarm 9mg PO daily 2 ER+ advanced disease, in patients who previously responded to hormone therapy GTx NCT01616758 April 2012–current; ongoing

Abbreviations: DHEA, Dehydroepiandrosterone; TNBC, Triple negative breast cancer.